Junshi Biosciences
Junshi Biosciences, officially known as Junshi Pharmaceutical Co., Ltd., is a leading biopharmaceutical company headquartered in China. Founded in 2012, the company has rapidly established itself in the global biotechnology landscape, focusing on the research, development, and commercialisation of innovative therapies, particularly in oncology and autoimmune diseases. With a strong presence in major operational regions including Asia and North America, Junshi Biosciences is recognised for its cutting-edge monoclonal antibody products. Notably, its flagship product, toripalimab, has garnered significant attention for its unique mechanism of action in cancer treatment. The company has achieved remarkable milestones, including successful partnerships and regulatory approvals, positioning itself as a key player in the biopharmaceutical industry.
DitchCarbon Score
How does Junshi Biosciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Junshi Biosciences's score of 22 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Junshi Biosciences's reported carbon emissions
In 2024, Junshi Biosciences reported total carbon emissions of approximately 26,800,750 kg CO2e. This figure includes about 5,307,750 kg CO2e from Scope 1 emissions and approximately 21,493,000 kg CO2e from Scope 2 emissions. Notably, the company has not disclosed any Scope 3 emissions data. Currently, Junshi Biosciences does not have any publicly stated reduction targets or climate pledges. The absence of specific initiatives or commitments indicates a potential area for future development in their climate strategy. The emissions data is sourced directly from Shanghai Junshi Biosciences Co., Ltd., with no cascading from a parent or related organization. As the biopharmaceutical industry increasingly focuses on sustainability, Junshi Biosciences may benefit from establishing clear climate commitments and reduction targets to align with industry standards and expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2024 | |
|---|---|
| Scope 1 | 5,307,750 |
| Scope 2 | 21,493,000 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Junshi Biosciences is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
